Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02930226 · ClinicalTrials.gov registry record · Phase 1
Ascending Doses of Autologous FDP vs FFP
A Phase 1 study of Freeze Dried Plasma in Healthy Volunteers, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02930226: Completed Phase 1 study of Freeze Dried Plasma in Healthy Volunteers, sponsored by U.S. Army Medical Research and Development Command.
NCT02930226 is a Phase 1 study of Freeze Dried Plasma in Healthy Volunteers that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02930226, a Phase 1 study of Freeze Dried Plasma in Healthy Volunteers, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Assess the safety of single infusions with RePlas FDP product at increasing fixed doses
Primary Outcome
Assess the safety of single infusions of FDP at increasing fixed doses of either 1 unit, 2 units, or 3 units in normal healthy subjects by evaluating vital signs during and after infusion
Conditions Studied
Interventions
- BIOLOGICAL Fresh Frozen Plasma (FFP)
- BIOLOGICAL Autologous Freeze Dried Plasma (FDP)
Study Locations (1)
Ohio
- Hoxworth Blood Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-02-13 |
| Est. Completion | 2018-08-02 |
| Phase | Phase 1 |
What the finished NCT02930226 record still lists
NCT02930226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Freeze Dried Plasma in Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Fresh Frozen Plasma (FFP) is the first listed.
NCT02930226 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02930226 about?
NCT02930226 is a clinical study titled "Ascending Doses of Autologous FDP vs FFP". Assess the safety of single infusions with RePlas FDP product at increasing fixed doses
What is the current status of trial NCT02930226?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2017-02-13. Estimated completion is 2018-08-02.
What conditions does trial NCT02930226 study?
This clinical trial studies the following conditions: Freeze Dried Plasma in Healthy Volunteers.
What interventions are being tested in trial NCT02930226?
The interventions under investigation include: Fresh Frozen Plasma (FFP) (BIOLOGICAL), Autologous Freeze Dried Plasma (FDP) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02930226?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02930226 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02930226's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI